Ciglitizone, >=99% (TLC)

Not available outside of the UK & Ireland.

Application

Ciglitizone has been used as a proliferator-activated receptor γ (PPARγ) agonist:to study its effects on cell proliferation in human melanocytesto study its effects on pigmentation and migration of human melanocytesIt also may be used to study its effects on cell cycle and apoptosis in monocytic cells.

Biochem/physiol Actions

Ciglitizone belongs to the class of thiazolidinediones and is a peroxisome proliferator-activated receptor γ (PPARγ) agonist. It exhibits anti-diabetic activity. Ciglitizone has the potential to treat tumor necrosis factor α (TNFα)-related apoptosis-inducing ligand (TRAIL)-refractory high-grade urothelial cancers.

Features and Benefits

This compound was developed by Takeda. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Packaging

5 mg in glass insert